Utility of Biochemical Markers of Bone Turnover in the Follow-up of Patients Treated with Bisphosphonates

[1]  H. Fleisch.  Bisphosphonates in Bone Disease: From the Laboratory to the Patient , 2000 .

[2]  Stephanie L. Lee,et al.  Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. , 1998, The Journal of clinical endocrinology and metabolism.

[3]  S. Leigh,et al.  Comparison of analytical performance and biological variability of three bone resorption assays. , 1997, Clinical chemistry.

[4]  C. Rosen,et al.  The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. , 1997, The Journal of clinical endocrinology and metabolism.

[5]  R. Parker,et al.  Diurnal Variation of Bone Mineral Turnover in Elderly Men and Women , 1997, Calcified Tissue International.

[6]  D. Eyre,et al.  Molecular basis and clinical application of biological markers of bone turnover. , 1996, Endocrine reviews.

[7]  V. T. Kung,et al.  Monoclonal antibody assay for free urinary pyridinium cross-links. , 1996, Clinical chemistry.

[8]  P. Delmas,et al.  Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  B. Leroux,et al.  Circadian variation in urinary excretion of bone collagen cross‐links , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  R. Eastell,et al.  Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. , 1995, Clinical chemistry.

[11]  Rees,et al.  Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. , 1995, Clinical chemistry.

[12]  C. Christiansen,et al.  Different effects of bisphosphonate and estrogen therapy on free and peptide‐bound bone cross‐links excretion , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  P. Delmas,et al.  Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. , 1994, The Journal of clinical endocrinology and metabolism.

[14]  H. Woitge,et al.  Direct, enzyme‐linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  C. Libanati,et al.  Biochemical markers of bone turnover for the clinical assessment of bone metabolism. , 1994, Rheumatic diseases clinics of North America.

[16]  J. Nisker,et al.  Long-Term Gonadotropin-Releasing Hormone Agonist With Standard Postmenopausal Estrogen Replacement Failed to Prevent Vertebral Bone Loss in Premenopausal Women , 1994 .

[17]  D. Eyre,et al.  A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross‐linked N‐telopeptides in urine , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  C. Christiansen,et al.  Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. , 1992, The Journal of clinical endocrinology and metabolism.

[19]  H. Genant,et al.  Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. , 1987, Annals of internal medicine.

[20]  J. Cramer,et al.  Use of oral contraceptives by women with epilepsy. , 1986, JAMA.

[21]  H K Genant,et al.  Quantitative Computed Tomography of Vertebral Spongiosa: A Sensitive Method for Detecting Early Bone Loss After Oophorectomy , 1982, Annals of internal medicine.